- Home
- VALN vs AQST Comparison
VALN vs AQST Comparison
Compare VALN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VALN | AQST |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.8M | 521.0M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | VALN | AQST |
|---|---|---|
| Price | $6.10 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $15.75 | $9.00 |
| AVG Volume (30 Days) | 128.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $4.00 | $10.08 |
| Revenue Next Year | $92.04 | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $5.43 | $2.20 |
| 52 Week High | $12.25 | $7.55 |
Technical Indicators
Market Signals| Indicator | VALN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 25.51 | 51.67 |
| Support Level | $5.69 | $3.70 |
| Resistance Level | $6.73 | $4.42 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 1.11 | 68.14 |
Price Performance
Historical ComparisonAbout VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.